https://www.selleckchem.com/pr....oducts/jh-x-119-01.h
Tacrolimus pharmacokinetics in obese (Ob) patients has been poorly studied. In this article, the authors explored the impact of obesity on tacrolimus exposure in kidney transplant recipients (KTRs) and estimated a more suitable initial dosage in this population. A retrospective, observational, monocentric case-control study was performed in obese KTRs (BMI 30 kg/m2) who received tacrolimus between 2013 and 2017 (initial dose 0.15 mg/kg/d) (actual weight). Nonobese (Nob) controls (BMI 30 kg/m2) were matched for age and sex.
Like
Comment
Share
